The Latest Breaking News from Pfizer Inc

With Russia’s plans to cut crude oil production threatening to tip an interest-rate-paranoid market into a fresh bout of volatility and sell-off, shares of fundamentally strong and profitable businesses, such as Taiwan Semiconductor Manufacturing Company (TSM), Walmart (WMT), and Pfizer (PFE), seem to be good investments now. Continue reading….

Although the Fed is expected to go slow with rate hikes, they are not expected to end anytime soon. Moreover, the possibility of a recession cannot be ruled out yet. Given the uncertainties, fundamentally sound dividend stocks Pfizer (PFE) and Sisecam (SIRE) could be a solid addition to your portfolio…

Amid concerns that an estimate-beating labor market tightness may embolden the Fed to keep pushing interest rates upward, fundamentally strong stocks Pfizer (PFE), Verizon (VZ), and AT&T (T) have deservedly found takers on Wall Street. Read on….

With the recent market rally hinged on hopes of an end to the Fed’s hawkishness in the foreseeable future, strong fundamentals of Pfizer (PFE) for excellent value could help investors secure decent risk-adjusted returns on their investments. Read on….

Shares of Pfizer (PFE), Centene (CNC), and Kellogg (K) could provide a solid foundation to new portfolios for sustained wealth creation, given the fundamental strength, consistent profitability, and resilient demand of these companies. Continue reading….

Looming recession fears, the Federal Reserve’s persistent monetary tightening plans, and stubbornly high inflation continue to impact investor sentiment. Hence, it could be wise to add fundamentally sound stocks Pfizer (PFE), Rio Tinto (RIO), and Lockheed Martin (LMT) to beat the market fluctuations this year. Continue reading….

Pfizer (PFE) topped Wall Street’s EPS and revenue estimates in the third quarter. Moreover, the company updated its guidance for fiscal 2022. Analysts expect the stock to rise more than 16% in the near term. Therefore, it could be wise to buy the stock now. Keep reading….

The updated COVID-19 boosters from Pfizer Inc/BioNTech SE and Moderna helped prevent symptomatic infections against the new XBB-related subvariants, offering new evidence of how the vaccines perform against these fast-spreading strains, U.S. officials said on Wednesday.

Rising chronic diseases, an aging population, and surging healthcare spending should boost the pharmaceutical industry’s growth prospects. Moreover, the pharmaceutical industry usually holds up well during market downturns due to relatively inelastic demand for their products and services. Therefore, fundamentally sound pharma stocks Johnson & Johnson (JNJ), AbbVie (ABBV), and…

Americans will get a clearer idea of how often they’ll roll up their sleeves for COVID-19 shots when advisers to U.S. regulators meet Thursday to discuss an immunization schedule that looks more like the one used for flu.

The Fed’s indication to keep raising interest rates through this year and looming recession fears will likely keep the stock market under pressure for the near term. Therefore, investors looking for stability amid an uncertain macroeconomic environment could consider buying fundamentally strong dividend-paying healthcare stocks Johnson & Johnson (JNJ), Pfizer…